AbbVie was spun off from Abbott Laboratories in 2013 and has grown into one of the world’s largest pharma companies, driven initially by Humira and now by its successor franchise (Skyrizi + Rinvoq). The Allergan acquisition (2020) added aesthetics and neuroscience.
Immunology, Oncology, Neuroscience, Aesthetics
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Humira (adalimumab) | Immunology | $14.4B |
| Skyrizi (risankizumab) | Immunology | $7.7B |
| Rinvoq (upadacitinib) | Immunology | $4.0B |
| Imbruvica (ibrutinib) | Oncology | $6.1B |
| Botox (onabotulinumtoxinA) | Aesthetics/Neuroscience | $2.8B |
| Vraylar (cariprazine) | Neuroscience | $2.7B |
AbbVie is the #5 pharma company. Successfully navigating Humira biosimilar cliff through Skyrizi + Rinvoq ($11.7B combined in 2023, projected $20B+ at peak). Allergan integration delivered diversification.
Revenue projected to grow to $60B+ by 2026 as Skyrizi/Rinvoq more than offset Humira decline. Pipeline expansion in IBD and new immunology indications key. Oncology bispecifics (epcoritamab) add growth.
AbbVie 2023 Annual Report (Form 10-K). Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.